Abstract:Metastatic melanoma patients are commonly treated with targeted (e.g., BRAF/MEK inhibitors) and/or immune checkpoint therapies and treatment efficacy is then assessed with radiological scans. These scans are highly effective for the staging of the disease but in terms of follow-up, there are several limitations including the inability to detect minimal residual disease (MRD). Circulating biomarkers are a viable solution to overcome these limitations, and this study sought to investigate a panel of melanoma-specific microRNA (miRNA) biomarkers in stage IV patients undergoing therapy. This panel had previously been assessed in treatment naïve stage IV patients, with members of the MELmiR-7 panel able to detect an increase in tumor burden in 100% of cases, as well as the ability to define overall survival (OS) superior to serum lactate dehydrogenase (LDH) and S100B levels (delta log-likelihood = 11, p< 0.001). In this multi-center longitudinal study, bloods were drawn from study participants from 2013-2015, with clinical follow-up until October 2018. The expression levels of the MELmiR-7 panel were assessed in serially collected serum (≥3 timepoints; ≥2-month intervals) collected from a total of 23 melanoma patients, treated with BRAF/MEK inhibitors and/or anti-CTLA4 and/or anti-PD-1. The goal was to determine if the panel could predict treatment success/failure, as well as patient OS, if treated with the same therapy. All miRNA panel members were measured using a sensitive real-time PCR assay at each time point, but only miR-4731 gave stable expression over the course of the therapy, with other panel members fluctuating post treatment. The stability of miR-4731 expression over time indicated that this marker was not affected by treatment type, rather changes in its expression were reflective of disease progression/regression (as determined by radiological images), thus making it an ideal biomarker. Importantly, across the cohort of 23 patients, miR-4731 expression had the ability to predict treatment outcome (Complete Response/Stable Disease (n=12) vs Melanoma Death (n=11)) for patients at ≥2 months post therapy vs baseline, with a high degree of precision (Mann Whitney, 2-tailed; p=0.0004). Area under the curve analysis also found miR-4731 expression to be highly sensitive and specific (AUC=0.91; p=0.0009) at predicting overall survival (OS). Furthermore, in Kaplan-Meier survival analysis, participants with high serum expression (≥2 months post therapy vs baseline) of miR-4731, had poor OS (p=0.0045; 14-month median survival) as compared with low serum miRNA expression which was predictive of a positive prognosis. In sum, assessment of this miRNA marker during therapy would permit early on-treatment prediction of patient outcomes, independent of imaging, to either continue to treat with current regimen, or to switch treatment modalities. Citation Format: Teresa Harris, Pauline Zaenker, Ashleigh C. McEvoy, H. Peter Soyer, Muhammad A. Khattak, Melanie Ziman, Michael Millward, Elin S. Gray, Mitchell S. Stark. Assessment of precision melanoma diagnostics: Circulating microrna expression to monitor late-stage treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7626.

Plasma circulating cell free messenger RNA as a potential biomarker of melanoma

Abstract LB-144: Molecular Signatures of Circulating Melanoma Cells for Monitoring Early Response to Immune Checkpoint Therapy

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Non-invasive Microrna Signatures from the Plasma of Breast Cancer Patients Reveals Sensitive and Specific Marker for Breast Cancer Screening

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients

Abstract 5160: Evaluation of circulating microRNAs as predictive and prognostic biomarkers for advanced melanoma patients

Abstract 7626: Assessment of precision melanoma diagnostics: Circulating microrna expression to monitor late-stage treatment

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma

Plasma proteomics in patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors

Abstract 1854: Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

Levels of Plasma Circulating Cell Free Nuclear and Mitochondrial DNA As Potential Biomarkers for Breast Tumors

Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients

Clinical Verification of Plasma Messenger RNA As Novel Noninvasive Biomarker Identified Through Bioinformatics Analysis for Lung Cancer.

The plasma exosomal miR-1180-3p serves as a novel potential diagnostic marker for cutaneous melanoma

Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment

A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients

Proteomic and metabolomic profiles of plasma-derived Extracellular Vesicles differentiate melanoma patients from healthy controls

Plasma Mrna As Liquid Biopsy in Individualized Chemotherapy of Gastric Cancer

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer